BioTime CEO Dr. Michael D. West to Lecture on Regenerative Medicine and Age Related Degenerative Disease
BioTime, Inc. (OTCBB:BTIM) announced today that Dr. Michael D. West will present a lecture entitled “Regenerative Medicine: Applications in Age Related Degenerative Disease” at the GTCbio New Applications For Aging Research Conference at the Hilton Harbor Island Hotel, 1960 Harbor Island Drive, in San Diego, California. Dr. West’s presentation is scheduled to start at 3:40 p.m. on Monday, January 7, 2008. Dr. West’s lecture will address how embryonic stem cells may be a source of immune compatible cell therapies for degenerative diseases associated with aging.
Dr. West will also discuss BioTime’s recent entry into the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc., which plans to develop new medical and research products using embryonic stem cell technology.
Embryome Sciences plans to develop and commercialize a technology platform called Embryomics™, a collection of research tools that can facilitate stem cell research by providing researchers with new products for the identification, scale-up, and purification of the many cell types that emerge from human embryonic stem cells.
About BioTime, Inc.
BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product Hextend® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com.
Forward Looking Statements
The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime’s operations and financial condition are discussed in BioTime’s Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.
Click here to join our email alert list.